RedHill Biopharma (RDHL) Enterprise Value (2022 - 2024)
RedHill Biopharma (RDHL) has disclosed Enterprise Value for 3 consecutive years, with -$1.9 million as the latest value for Q4 2024.
- Quarterly Enterprise Value rose 66.21% to -$1.9 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$1.9 million through Dec 2024, up 66.21% year-over-year, with the annual reading at -$1.9 million for FY2024, 66.21% up from the prior year.
- Enterprise Value for Q4 2024 was -$1.9 million at RedHill Biopharma, up from -$5.6 million in the prior quarter.
- The five-year high for Enterprise Value was -$1.9 million in Q4 2024, with the low at -$20.0 million in Q4 2022.
- Average Enterprise Value over 3 years is -$9.1 million, with a median of -$5.6 million recorded in 2023.
- The sharpest move saw Enterprise Value soared 72.11% in 2023, then surged 66.21% in 2024.
- Over 3 years, Enterprise Value stood at -$20.0 million in 2022, then skyrocketed by 72.11% to -$5.6 million in 2023, then soared by 66.21% to -$1.9 million in 2024.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$1.9 million, -$5.6 million, and -$20.0 million for Q4 2024, Q4 2023, and Q4 2022 respectively.